Medicine & pharma · Pipeline & development
Interlude Biopharma Launches at the International Celiac Disease Symposium and Announces Prevention-Focused Phase 3 Clinical Trial
First Celiac Prevention Study Expected to Start in First Quarter of 2027 MIAMI and MELBOURNE, Australia, Nov. 19, 2026 /PRNewswire/ -- Mark Paresky, co-founder and executive chairman of Interlude Biopharma Co., today announced the company's public launch at the 21st International Celiac...
Original source
Read the source — prnewswire.com ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.